ABVC

$0.99+0.51%visit website

ABVC BIOPHARMA, INC.

Market Cap

$26M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.46

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

2.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	796	(500)
Gross profit	796
Research & development	30	29	33	23	115
Selling, general & administrative	798	784	752	504	2,838
Total operating expenses	1,964	2,199	1,572	780	6,515
Operating income	(1,964)	(2,199)	(1,572)	(780)	(6,515)
Interest expense	31	33	49	42	155
Pretax income	(2,083)	(3,016)	(1,690)	(810)	(7,600)
Income tax	0.53	0.00
Net income	(2,042)	(2,767)	(1,560)	(737)	(7,107)
EPS (basic) ($)	(0.09)		(0.06)	(0.03)	(0.29)
EPS (diluted) ($)	(0.09)		(0.06)	(0.03)	(0.29)
Weighted avg. shares (basic)	23,257		25,449	26,059
Weighted avg. shares (diluted)	23,257		25,449	26,059

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 60 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

8 filings in 12 months · 3 with priority itemsFull history →

Filed	Items	Filing
Nov 2, 2026 accepted 9:51 AM ET	1.01Material agreement1.02Agreement terminated2.03New debt obligation3.02Unregistered equity sale5.07Shareholder vote7.01Reg FD disclosure	Document SEC ↗
Aug 27, 2026 accepted 8:30 AM ET	1.01Material agreement2.01Acquisition / disposition7.01Reg FD disclosure	Document SEC ↗
Aug 12, 2026 accepted 11:50 AM ET	8-K/A 8.01Other events	Document SEC ↗
Aug 4, 2026 accepted 9:12 PM ET	8.01Other events	Document SEC ↗
Jul 2, 2026 accepted 4:01 PM ET	4.01Auditor change	Document SEC ↗
Mar 27, 2026 accepted 4:05 PM ET	5.07Shareholder vote	Document SEC ↗
Mar 3, 2026 accepted 4:14 PM ET	2.02Earnings release4.02Non-reliance (restatement)	Document SEC ↗
Jan 16, 2026 accepted 4:30 PM ET	8-K/A 3.02Unregistered equity sale	Document SEC ↗
Nov 3, 2025 accepted 7:30 AM ET	2.02Earnings release	Document SEC ↗
Oct 30, 2025 accepted 8:31 AM ET	5.02Officer / director change	Document SEC ↗